Chen DS - Search Results

1

Prospective role of liquid biopsy for early screening in laryngeal cancer.

Gong XY, Chen HB, Lu ZY, Zhu C, Chen DS, Chen X. Gong XY, et al. Among authors: chen ds, chen hb, chen x. Invest New Drugs. 2023 Jun;41(3):376-379. doi: 10.1007/s10637-023-01365-4. Epub 2023 May 2. Invest New Drugs. 2023. PMID: 37129839 No abstract available.

2

Significant benefit of everolimus in a patient with urothelial bladder cancer harboring a rare M1043I mutation of PIK3CA.

Pan S, Li S, Xiao M, Chen D, Li J. Pan S, et al. Invest New Drugs. 2021 Aug;39(4):1197-1199. doi: 10.1007/s10637-021-01103-8. Epub 2021 Mar 20. Invest New Drugs. 2021. PMID: 33745098

3

Icotinib, an effective treatment option for patients with lung adenocarcinoma harboring compound EGFR L858R and A871G mutation.

Jin LL, Wu ZZ, Wang YL, Chen DS, Li S, Xiao M, Zhao X. Jin LL, et al. Among authors: chen ds. Invest New Drugs. 2021 Oct;39(5):1419-1421. doi: 10.1007/s10637-021-01108-3. Epub 2021 Apr 9. Invest New Drugs. 2021. PMID: 33835358

4

Helicobacter pylori infection as a potential favorable factor for immune checkpoint inhibitor therapy for gastric cancer.

Zhang MJ, Chen DS, Li S, Chen L, Qi YX, Zhang CJ. Zhang MJ, et al. Among authors: chen l, chen ds. Invest New Drugs. 2021 Oct;39(5):1436-1438. doi: 10.1007/s10637-021-01122-5. Epub 2021 Apr 29. Invest New Drugs. 2021. PMID: 33913072

5

Genomic landscape and tumor mutation burden analysis of Chinese patients with sarcomatoid carcinoma of the head and neck.

Chen HB, Gong XY, Li W, Chen DS, Zhao LL, Li S, Xiao MZ, Cheng L, Chen X. Chen HB, et al. Among authors: chen ds, chen x. Oral Oncol. 2021 Oct;121:105436. doi: 10.1016/j.oraloncology.2021.105436. Epub 2021 Aug 6. Oral Oncol. 2021. PMID: 34371452

6

NOTCH1 mutation associates with impaired immune response and decreased relapse-free survival in patients with resected T1-2N0 laryngeal cancer.

Gong XY, Chen HB, Zhang LQ, Chen DS, Li W, Chen DH, Xu J, Zhou H, Zhao LL, Song YJ, Xiao MZ, Deng WL, Qi C, Wang XR, Chen X. Gong XY, et al. Among authors: chen ds, chen dh, chen hb, chen x. Front Immunol. 2022 Jul 15;13:920253. doi: 10.3389/fimmu.2022.920253. eCollection 2022. Front Immunol. 2022. PMID: 35911687 Free PMC article.

7

Gastrointestinal signet ring cell malignancy: current advancement and future prospects.

Hong W, Hu Q, Tan Y, Duan Q, Zhang Q, Chen D, Qi C, Wang D. Hong W, et al. Invest New Drugs. 2023 Dec;41(6):861-869. doi: 10.1007/s10637-023-01403-1. Epub 2023 Oct 21. Invest New Drugs. 2023. PMID: 37864727 Review.

8

Immunoneoadjuvant therapy with immune checkpoint inhibitors of gastric cancer: an emerging exemplification : Immunoneoadjuvant therapy of gastric cancer.

Yao G, Yuan J, Duan Q, Tan Y, Zhang Q, Chen D, Chen J. Yao G, et al. Invest New Drugs. 2024 Feb;42(1):1-13. doi: 10.1007/s10637-023-01406-y. Epub 2023 Nov 16. Invest New Drugs. 2024. PMID: 37971628 Review.

9

RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma.

Jiang Y, Hu X, Wang Z, Zhang Q, Chen D, Zhao P. Jiang Y, et al. Invest New Drugs. 2024 Feb;42(1):60-69. doi: 10.1007/s10637-023-01413-z. Epub 2023 Dec 10. Invest New Drugs. 2024. PMID: 38071684

10

Molecular and immunological characteristics of postoperative relapse in lymph node-positive esophageal squamous cell cancer.

Pan HG, Fang HL, Zhu C, Li S, Yi H, Zhang X, Yin XY, Song YJ, Chen D, Yin CT. Pan HG, et al. Cancer Med. 2024 May;13(9):e7228. doi: 10.1002/cam4.7228. Cancer Med. 2024. PMID: 38733174 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,033 results

Search Page